Authors

Genmab and AbbVie Sponsored Content; OncLive Article with Tahi Ahmadi and Asud Khaliq

Latest:

Treatment Option for Adult Patients with 3L+ Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Many people living with diffuse large B-cell lymphoma (DLBCL) continue to experience significant treatment challenges. Genmab and AbbVie discuss the current DLBCL treatment landscape and an effort as part of a collaboration between the two companies for people diagnosed with relapsed or refractory DLBCL.

Paolo F. Caimi, MD

Latest:

Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL

Paolo Caimi, MD, discusses the rationale behind evaluating LMY-920, a novel BAFF CAR T-cell therapy, in relapsed/refractory non-Hodgkin lymphoma.

Jeffrey S. Miller, MD

Latest:

Dr Miller on the Use of NK Cell Therapy in Hematologic Malignancies

Jeffrey S. Miller, MD, discusses research with natural killer cell therapy in patients with hematologic malignancies and other cancers.

Domenica Lorusso, MD, PhD

Latest:

Dr Lorusso on Key Takeaways About Relacorilant Combination Treatment in Ovarian Cancer

Domenica Lorusso, MD, PhD, discusses the selective glucocorticoid receptor modulator relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.

Christine Sam, MD

Latest:

Dr. Sam on Sequencing Tucatinib and Trastuzumab Deruxtecan in HER2+ Breast Cancer

Christine Sam, MD, discusses strategies for sequencing tucatinib and fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive breast cancer.

Indiana University School of Medicine

Latest:

$3.3 Million Grant to IU Researchers Aims to Increase Colorectal Cancer Screening in Rural Indiana

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center are addressing the low colorectal cancer screening rates in rural Indiana communities with a five-year, $3.3 million grant from the National Cancer Institute.

Amma Asare, MD, PhD

Latest:

Dr Asare on the Elevated Risk of Secondary Leukemias in PARP Inhibitors in Gynecologic Cancers

Amma Asare, MD, PhD, discusses the elevated risk of therapy-related myeloid neoplasms or secondary leukemias in gynecologic cancers after a PARP inhibitor.

John Molina, MD, MEd

Latest:

Clinical Trials and Real-World Data on Brexu-Cel

Panelists discuss how the dosing and lymphodepletion regimens of brexucabtagene autoleucel (brexu-cel), tisagenlecleucel (tisa-cel), and obecabtagene autoleucel (obe-cel) differ, with insights into obe-cel’s double infusion approach, as well as a deeper dive into the ZUMA-3 trial’s design and data updates with brexu-cel in relapsed/refractory acute lymphoblastic leukemia (R/R ALL).

Andrew Ip, MD, MS

Latest:

Dr. Ip on the Utility of Investigational Treatments for COVID-19 in Oncology

Andrew Ip, MD, MS, discusses the utility of investigational treatments for COVID-19 in patients with cancer.

David Sommerhalder, MD

Latest:

Dr Sommerhalder on the Potential Utility of Single-Agent RMC-6291 in KRAS G12C–Mutant CRC

David Sommerhalder, MD, discusses the potential for RMC-6291 as a single agent in KRAS G12C–mutated advanced colorectal cancer.

Julia Liu, MD

Latest:

Dr. Liu on Enrolling Diverse Patients in the PREEMPT-CRC Trial in CRC

Julia Liu, MD, discusses enrolling diverse patients in the PREEMPT CRC trial in colorectal cancer.

Martin Cannon, PhD

Latest:

Dr Cannon on the Use of Dendritic Cell Vaccines in Ovarian Cancer

Martin Cannon, PhD, discusses the use of dendritic cell vaccines and immune checkpoint inhibitors in ovarian cancer.

Stephen Bagley, MD, MSCE

Latest:

Bagley Summarizes the ACTION trial of ONC201 in H3 K27M–Mutant Diffuse Midline Gliomas

Dr Bagley discusses the evaluation of the small molecule ONC201 in the phase 3 ACTION trial in H3 K27M–mutant diffuse midline gliomas.

Peter Hillmen, MD, PhD

Latest:

Dr. Hillmen on Results With Acalabrutinib in CLL

Peter Hillmen, MD, PhD, discusses results reported with acalabrutinib in patients with chronic lymphocytic leukemia, as demonstrated in a phase 3 trial.

Mitchell Machtay, MD

Latest:

Dr Machtay on the Prognostic Value of Pre-Treatment Immunologic Biomarker Levels in NSCLC

Mitchell Machtay, MD, discusses the association between the levels of circulating immune biomarkers prior to immunotherapy and survival outcomes in patients with stage III non-small cell lung cancer.

Bhavana Bhatnagar, DO

Latest:

Dr Bhatnagar on AlloSCT Outcomes After Blinatumomab/Chemo in MRD-Negative B-ALL

Bhavana Bhatnagar, DO, discusses outcomes for allogeneic stem cell transplantation after blinatumomab plus chemotherapy in B-ALL.

Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center

Latest:

Expanding Treatment Options for HER2+ Breast Cancer

David Weintritt, MD, FACS

Latest:

Empowering Breast Surgeons: A Call for Collective Action

As survival rates continue to rise for patients with breast cancer, innovations are still needed to advance surgical care for these patients.

Montefiore Einstein Comprehensive Cancer Center

Latest:

Montefiore Einstein Comprehensive Cancer Center Upholds Top Honor for Cancer Care

MECCC Earns Three-Year Accreditation from the Commission on Cancer of the American College of Surgeons – Again!

Idalid Franco, MD, MPH

Latest:

Dr Franco on the Integration of Immunotherapy Treatment in Endometrial Cancer

Idalid Franco, MD, MPH, discusses the use of radiation therapy and immunomodulatory agents in the treatment of endometrial cancer.